Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost

Current Medical Research and Opinion

Volumn 22, Issue 5, 2006, Pages 971-976

  Covert, David ^a   Robin, Alan L ^b  

^a ALCON RESEARCH LTD   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adjunctive drug; Bimatoprost; Glaucoma; Latanoprost; Prostaglandin analog; Travoprost

Indexed keywords

BIMATOPROST; LATANOPROST; PROSTAGLANDIN; TRAVOPROST;

ADULT; AGED; ARTICLE; BLINDNESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE; POPULATION RESEARCH; PRESCRIPTION; RISK ASSESSMENT; RISK FACTOR; STUDENT T TEST;

AGED; AMIDES; CLOPROSTENOL; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; MALE; PROSTAGLANDINS F, SYNTHETIC; PROSTAGLANDINS, SYNTHETIC;

EID: 33745056751     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X104777     Document Type: Article

References (23)

1. Lichter PR. Expectations from clinical trials: results of the early manifest glaucoma trial. Arch Ophthalmol 2002;120:1371-2
2. American Academy of Ophthalmology. Types of glaucoma. Available form www.medem.com [last accessed 3-10-06]
3. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS), IX: comparison of glaucoma outcomes in black and white patients within treatment groups. Am J Ophthalmol 2001;132:311-20
4. Kass M, Heuer D, Higginbotham E, et al. The Ocular Hypertension Treatment Study (OHTS): a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
5. Heijl A, Leske C, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 2002;120:1268-79
6. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53
7. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol 2000;10:95-104
8. Fellman RL, Sullivan EK, Ratliff M, et al. Travoprost Study Group. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology 2002;109:998-1008
9. Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001;45:S361-S168
10. Soltau JB, Zimmerman TJ. Changing paradigms in the medical treatment of glaucoma. Surv Ophthalmol 2002;47:S2-S5
11. VanderZanden JA, Valuck RJ, Bunch CL, et al. Systemic adverse effects of ophthalmic beta-blockers. Ann Pharmacother 2001;35:1633-7
12. Roter DL, Hall JA, Merisca R, et al. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care 1998;36:1138-61
13. Covert D, Robin AL, Novack GD. Systemic medications and glaucoma patients. Ophthalmology 2005;112:1849
14. Meickenbaum D, Turk DC. Facilitating treatment adherence: a practitioner's guidebook. New York: Plenum Press; 1987. p. 20-2
15. Whitson JT, Netland PA, Hermes-DeSantis ER. When and what to add to prostaglandin therapy. Rev Ophthalmol 2005;Aug:62-9
16. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005;112:863-8
17. Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol 2004;137:S13-S16
18. Plosher GL, Kean SJ. Bimatoprost: a pharmacoeconomic review of its use in open-angle glaucoma and ocular hypertension. Pharmacoeconomics 2006;24:297-314
19. Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. Pharmacoeconomics 2006;24:251-64
20. Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
21. Olthoff CMG, Schouten JSAG, van de Borne BW, et al. Noncompliance with ocular hypotensive treatments in patients with glaucoma or ocular hypotension. Ophthalmology 2005;112:953-61
22. Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology 2006;113:431-6
23. Serle JB, Toor A, Fahim MM, et al. The effect of varying dosing interval on the efficacy of intraocular pressure lowering drugs. ARVO abstracts 2004 [abstract 971]